

April 24, 2024

Samuel Kintz
Chief Executive Officer
Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301

Therapeutics, Inc.
Statement on Form S-3
2024

Re: Enliven
Registration
Filed April 18,
File No. 333-278801

Dear Samuel Kintz:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Stacey Gama at 202-551-3188 with any questions.

Please contact Doris

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Rachel Nagashima, Esq.